Patents Assigned to ZHEJIANG CANCER HOSPITAL
  • Use of non-coding RNA SNHG17 as biomarker and therapeutic target
    Patent number: 11866707
    Abstract: This invention discloses the use of non-coding RNA SNHG17 as a biomarker and a therapeutic target that relates to the technical field of tumor biotherapy. This invention discloses a use of the non-coding RNA SNHG17 for the manufacture of a detection agent for predicting the drug resistance of fulvestrant. This invention also discloses the use of shRNA for inhibiting non-coding RNA SNHG17 expression. This shRNA can knockdown the expression of the non-coding RNA SNHG17 efficiently. In this way, the sensitivity of fulvestrant-resistant breast cancer cells can be increased. So this invention has good prospects for drug development.
    Type: Grant
    Filed: October 21, 2022
    Date of Patent: January 9, 2024
    Assignee: ZHEJIANG CANCER HOSPITAL
    Inventors: Lei Lei, Xiaojia Wang
  • USE OF NON-CODING RNA SNHG17 AS BIOMARKER AND THERAPEUTIC TARGET
    Publication number: 20230374516
    Abstract: This invention discloses the use of non-coding RNA SNHG17 as a biomarker and a therapeutic target that relates to the technical field of tumor biotherapy. This invention discloses a use of the non-coding RNA SNHG17 for the manufacture of a detection agent for predicting the drug resistance of fulvestrant. This invention also discloses the use of shRNA for inhibiting non-coding RNA SNHG17 expression. This shRNA can knockdown the expression of the non-coding RNA SNHG17 efficiently. In this way, the sensitivity of fulvestrant-resistant breast cancer cells can be increased. So this invention has good prospects for drug development.
    Type: Application
    Filed: October 21, 2022
    Publication date: November 23, 2023
    Applicant: ZHEJIANG CANCER HOSPITAL
    Inventors: Lei LEI, Xiaojia WANG